Select your country

Websites worldwide

Select a country to go to the website of the respective STADA sales company.

Australia (1)

Austria (1)

Belarus (1)

Belgium (1)

Bosnia-Herzegovina (1)

Bulgaria (1)

China (1)

Croatia (1)

Czech Republic (2)

Denmark (1)

France (1)

Germany (3)

Hungary (1)

Ireland (1)

Italy (1)

Montenegro (1)

Netherlands (2)

Poland (1)

Portugal (1)

Romania (1)

Saudi Arabia (1)

Serbia (1)

Slovakia (1)

Slovenia (1)

Spain (1)

Switzerland (1)

The Phillippines (1)

United Kingdom (3)

Vietnam (2)

< Back

STADA: Successful placement of a corporate bond in the amount of Euro 350 million

  • 29/05/2013
  • Investor News
  • Press Release

Bad Vilbel, May 29, 2013 –

Today, on May 29, 2013, STADA Arzneimittel AG has successfully placed a corporate bond with a fixed interest rate and a volume in the amount of Euro 350 million.


The bond has a term of five years with an annual interest rate of 2.25 percent. The issue price amounts to 99.417 percent. The denomination is Euro 1,000. The bond will be admitted to trading on the regulated market of the Luxembourg Stock Exchange. The identification numbers are: German Securities Code (WKN): A1TNEC, ISIN: XS0938218400, Common Code: 093821840.


The order book for the emission was oversubscribed by more than three times.
The bond was placed both with institutional investors and private investors in more than seven countries.
The joint lead managers for this transaction are Commerzbank Aktiengesellschaft, Deutsche Bank AG (London Branch), DZ BANK AG Deutsche Zentral-Genossenschaftsbank (Frankfurt am Main) and Landesbank Hessen-Thüringen Girozentrale.


STADA intends to use the proceeds from the issue for general financing purposes.
In addition to a corporate bond successfully issued back in 2010 (see the Company's corporate news of April 14, 2010), STADA now has a second bond on the capital markets which contributes to the optimization of financing costs.

For information regarding the securities mentioned in this corporate news, please refer to the respective securities prospectus dated May 24, 2013, published on the internet site of the Luxembourg Stock Exchange (www.bourse.lu). Nothing in this corporate news constitutes an offer of securities, an invitation to subscribe to or purchase securities, any advice or other service in relation to the securities, nor does the information contained herein qualify as the basis for a contractual or other obligation. In particular, the securities referred to in this corporate news may not be offered within the United States of America or to persons residing in the United States of America or to those who count as US Persons in the sense of Regulation S of the U.S. Securities Act of 1933. The securities have not been, and will not be, registered according to the U.S. Securities Act. The information contained in this corporate news is not intended for distribution to or within the United States of America.
For more information, please contact:


STADA Arzneimittel AG
Corporate Communications
D-61118 Bad Vilbel
Tel.: +49 6101 603-113
Fax: +49 6101 603-506
e-mail: [email protected]